1. Search Result
Search Result
Results for "

CSF-1R

" in MedChemExpress (MCE) Product Catalog:

71

Inhibitors & Agonists

6

Inhibitory Antibodies

4

Natural
Products

22

Recombinant Proteins

3

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162309

    c-Fms Cancer
    CSF1R-IN-20 (compound 7a) is a CSF-1R Inhibitor with an IC50 value of 467 nM. CSF1R-IN-20 inhibits CSF-1R auto-phosphorylation [1].
    CSF1R-IN-20
  • HY-157996

    c-Fms Neurological Disease
    CSF1R-IN-21 (compound 7e) is a CSF-1R Inhibitor with an IC50 value of 31 nM. CSF1R-IN-21 inhibits CSF-1R auto-phosphorylation and can be used for the research of neurodegenerative diseases [1].
    CSF1R-IN-21
  • HY-RS03228

    Small Interfering RNA (siRNA) Others

    CSF1R Human Pre-designed siRNA Set A contains three designed siRNAs for CSF1R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CSF1R Human Pre-designed siRNA Set A
    CSF1R Human Pre-designed siRNA Set A
  • HY-RS03229

    Small Interfering RNA (siRNA) Others

    Csf1r Mouse Pre-designed siRNA Set A contains three designed siRNAs for Csf1r gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Csf1r Mouse Pre-designed siRNA Set A
    Csf1r Mouse Pre-designed siRNA Set A
  • HY-RS03230

    Small Interfering RNA (siRNA) Others

    Csf1r Rat Pre-designed siRNA Set A contains three designed siRNAs for Csf1r gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Csf1r Rat Pre-designed siRNA Set A
    Csf1r Rat Pre-designed siRNA Set A
  • HY-147608

    c-Fms Neurological Disease
    CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research [1].
    CSF1R-IN-7
  • HY-144040

    c-Fms Cancer
    CSF1R-IN-4 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104) [1].
    CSF1R-IN-4
  • HY-144041

    c-Fms Cancer
    CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) [1].
    CSF1R-IN-5
  • HY-144042

    c-Fms Cancer
    CSF1R-IN-6 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-6 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-6 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 5) [1].
    CSF1R-IN-6
  • HY-147611

    c-Fms Cancer
    CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC50 of 0.005 μM [1].
    CSF1R-IN-10
  • HY-147609

    c-Fms Cancer
    CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM [1].
    CSF1R-IN-8
  • HY-147610

    c-Fms Cancer
    CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC50 of 0.028 μM [1].
    CSF1R-IN-9
  • HY-157422

    c-Fms Cancer
    CSF1R-IN-19 is a potent inhibitor of CSF1R. CSF1R-IN-19 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-19 has the potential for the research of cancer [1].
    CSF1R-IN-19
  • HY-101774
    CSF1R-IN-1
    1 Publications Verification

    c-Fms Cancer
    CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
    CSF1R-IN-1
  • HY-158363

    c-Fms Neurological Disease Inflammation/Immunology Cancer
    CSF1R-IN-25 (compound 36) is an orally effective CSF1R inhibitor. CSF1R-IN-25 can be used to study cancer, inflammation, and neurodegeneration [1].
    CSF1R-IN-25
  • HY-155550

    c-Fms Inflammation/Immunology
    CSF1R-IN-17 (compound 9) is a potent and selective CSF1R antagonist, with an IC50 of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation [1].
    CSF1R-IN-17
  • HY-160842

    c-Fms Neurological Disease
    CSF1R-IN-24 (Example 134) is an orally active CSF1R inhibitor. CSF1R-IN-24 significantly inhibits the survival of human ipSC-derived microglia (hiPSC-MG) [1].
    CSF1R-IN-24
  • HY-158148

    c-Fms Neurological Disease Inflammation/Immunology
    CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC50 of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable [1].
    CSF1R-IN-23
  • HY-155001

    c-Fms Others
    CSF1R-IN-15 (compound 23) is an inhibitor targeting CSF1R. The colony-stimulating factor-1 receptor (CSF1R) is a tyrosine kinase embedded in the cell membrane of macrophages. The receptor is activated by colony-stimulating factor-1 (CSF-1) and interleukin-34, and signaling via CSF1R is crucial for the differentiation, proliferation, and survival of macrophages [1].
    CSF1R-IN-15
  • HY-139990

    c-Fms Cancer
    CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity [1].
    CSF1R-IN-3
  • HY-161084

    c-Fms Neurological Disease Cancer
    CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases [1].
    CSF1R-IN-18
  • HY-162415

    c-Fms Apoptosis Cancer
    CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 + T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 + T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs [1].
    CSF1R-IN-22
  • HY-147617

    c-Fms Cancer
    CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1) [1].
    CSF1R-IN-14
  • HY-147615

    c-Fms Cancer
    CSF1R-IN-12 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1) [1].
    CSF1R-IN-12
  • HY-147616

    c-Fms Cancer
    CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) [1].
    CSF1R-IN-13
  • HY-111787

    TPX-0022; CSF1R-IN-2

    Src c-Met/HGFR c-Fms Cancer
    Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively [1].
    Elzovantinib
  • HY-153277

    TAM Receptor c-Fms Neurological Disease
    Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor [1].
    Axl/Mer/CSF1R-IN-2
  • HY-P99259

    FPA 008; Anti-Human CSF1R Recombinant Antibody

    c-Fms Inflammation/Immunology Cancer
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research [1] .
    Cabiralizumab
  • HY-159503A

    3D185; HH185

    FGFR c-Fms Cancer
    Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and CSF-1R; The IC50 values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity [1].
    Segigratinib hydrochloride
  • HY-153012

    TAM Receptor c-Fms Cancer
    Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with Kds of <0.1 μM [1].
    Axl/Mer/CSF1R-IN-1
  • HY-P99368

    MCS110; Anti-Human B7-H3

    c-Fms Metabolic Disease Cancer
    Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis [1] .
    Lacnotuzumab
  • HY-P99245

    RG 7155; RO 5509554

    c-Fms Cancer
    Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) [1] .
    Emactuzumab
  • HY-117244
    AZD7507
    1 Publications Verification

    c-Fms Cancer
    AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
    AZD7507
  • HY-124526

    Ibcasertib; CS2164

    VEGFR PDGFR c-Kit Aurora Kinase c-Fms Cancer
    Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects [1].
    Chiauranib
  • HY-153920

    ABSK021

    c-Fms Cancer
    Pimicotinib is a CSF1R inhibitor with antitumor activity [1].
    Pimicotinib
  • HY-122906

    c-Fms Inflammation/Immunology
    JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis [1].
    JTE-952
  • HY-101526

    RA03546849

    c-Fms Inflammation/Immunology
    GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
    GENZ-882706
  • HY-159108

    c-Fms Cardiovascular Disease
    AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (Ki=8 nM; IC50=6 nM). AZ683 has good oral bioavailability. [ 11C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) [1] .
    AZ683
  • HY-119942

    c-Fms Cancer
    c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM [1].
    c-Fms-IN-8
  • HY-101768
    PRN1371
    1 Publications Verification

    FGFR c-Fms Cancer
    PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively [1].
    PRN1371
  • HY-159838

    c-Fms Cancer
    Enrupatinib is a colony-stimulating factor 1 receptor (CSF1R) inhibitor with antitumor activity [1].
    Enrupatinib
  • HY-112451

    c-Fms Inflammation/Immunology
    cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. CSF-1 is a cytokine [1].
    cFMS Receptor Inhibitor II
  • HY-P99452

    SNDX-6352

    c-Fms Inflammation/Immunology Cancer
    Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases [1] .
    Axatilimab
  • HY-132935

    c-Fms Inflammation/Immunology Cancer
    BPR1R024 is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology [1].
    BPR1R024
  • HY-12768
    Sotuletinib
    20+ Cited Publications

    BLZ945

    c-Fms Cancer
    Sotuletinib (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs [1].
    Sotuletinib
  • HY-12768A
    Sotuletinib hydrochloride
    20+ Cited Publications

    BLZ945 hydrochloride

    c-Fms Cancer
    Sotuletinib (BLZ945) hydrochloride is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs [1].
    Sotuletinib hydrochloride
  • HY-161025

    c-Fms VEGFR Cancer
    SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM [1].
    SYHA1813
  • HY-126297

    c-Fms Inflammation/Immunology Cancer
    c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 has anti-tumor activity [1].
    c-Fms-IN-10
  • HY-16749A
    Pexidartinib hydrochloride
    Maximum Cited Publications
    83 Publications Verification

    PLX-3397 hydrochloride

    c-Fms c-Kit Apoptosis Cancer
    Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity [1].
    Pexidartinib hydrochloride
  • HY-132935A

    c-Fms Inflammation/Immunology Cancer
    BPR1R024 mesylate is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 mesylate is the equivalent of BPR1R024 (HY-132935). BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology [1].
    BPR1R024 mesylate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: